- Home
- KOD vs PHAT Comparison
KOD vs PHAT Comparison
Compare KOD & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KOD | PHAT |
|---|---|---|
| Founded | 2009 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 942.6M |
| IPO Year | 2018 | 2019 |
Fundamental Metrics
Financial Performance| Metric | KOD | PHAT |
|---|---|---|
| Price | $26.05 | $15.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $26.57 | $17.33 |
| AVG Volume (30 Days) | ★ 1.1M | 911.3K |
| Earning Date | 11-13-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $147,190,000.00 |
| Revenue This Year | N/A | $220.37 |
| Revenue Next Year | N/A | $83.14 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 460.30 |
| 52 Week Low | $1.92 | $2.21 |
| 52 Week High | $31.18 | $18.31 |
Technical Indicators
Market Signals| Indicator | KOD | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 51.48 | 48.14 |
| Support Level | $23.92 | $15.43 |
| Resistance Level | $28.11 | $18.09 |
| Average True Range (ATR) | 2.28 | 0.91 |
| MACD | -0.49 | -0.12 |
| Stochastic Oscillator | 27.41 | 17.66 |
Price Performance
Historical ComparisonAbout KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.